Antibody responses were measured pre-boost at 6 months after primary dose vaccination and compared to responses at one month after a homologous boost. Plasma samples from patients with either no prior infection (black), infected with D614G (blue), and infected with Beta (red) were tested for binding (A), antibody-dependent cellular cytotoxicity (ADCC) activity (B) and neutralization (C) to the D614G variant. Geometric mean values are shown below the graphs. Binding antibodies were quantified by OD450nm values, ADCC activity was measured in FcγRIIIa signaling and neutralization was indicated by ID50 values. All experiments were performed in duplicate. The Wilcoxon matched-pairs signed rank test was used to determine statistical significance ...
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses a...
BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has b...
BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has b...
Participants with no prior infection (black, Group 1), infected with D614G (blue, Group 2) or infect...
Plasma samples from participants with no prior infection (black), infected with D614G (blue) or infe...
Plasma samples from participants with no prior infection (black), infected with D614G (blue) or infe...
T cell cytokine responses were measured at 6 months post-vaccination and compared to responses at on...
Plasma samples from participants with either no prior infection (black), infected with D614G (blue),...
Plasma was tested at baseline (pre-vax) for antibody binding (A), ADCC activity (B) and neutralizati...
Plasma was tested for cross-reactivity in antibody binding (A), ADCC activity (B) and neutralization...
This study pictures the humoral response of 100 vaccinees to Pfizer/BioNTech COVID-19 vaccine over a...
IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants brought wa...
ABSTRACT: Objective: To determine whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-...
3a. Antibodies against SARS-CoV-2 Wuhan-hu-1 spike protein as measured by ELISA at baseline and two ...
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses a...
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses a...
BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has b...
BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has b...
Participants with no prior infection (black, Group 1), infected with D614G (blue, Group 2) or infect...
Plasma samples from participants with no prior infection (black), infected with D614G (blue) or infe...
Plasma samples from participants with no prior infection (black), infected with D614G (blue) or infe...
T cell cytokine responses were measured at 6 months post-vaccination and compared to responses at on...
Plasma samples from participants with either no prior infection (black), infected with D614G (blue),...
Plasma was tested at baseline (pre-vax) for antibody binding (A), ADCC activity (B) and neutralizati...
Plasma was tested for cross-reactivity in antibody binding (A), ADCC activity (B) and neutralization...
This study pictures the humoral response of 100 vaccinees to Pfizer/BioNTech COVID-19 vaccine over a...
IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants brought wa...
ABSTRACT: Objective: To determine whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-...
3a. Antibodies against SARS-CoV-2 Wuhan-hu-1 spike protein as measured by ELISA at baseline and two ...
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses a...
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses a...
BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has b...
BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has b...